Trastuzumab Deruxtecan Demonstrates Efficacy in Residual HER2-Positive Early Breast Cancer: Analysis of Phase III Trial Data

A recent phase III randomized controlled trial published in the New England Journal of Medicine demonstrated significant clinical benefit for trastuzumab deruxtecan in patients with residual HER2-positive early breast cancer following neoadjuvant therapy. The findings support adjuvant antibody-drug conjugate therapy in this high-risk population.